INCR
InterCure Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$5.42
+3.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 270.2M | 270.2M | 238.8M | 355.6M | 388.7M |
| Cost of Revenue | 229.5M | 237.0M | 208.6M | 250.5M | 233.6M |
| Gross Profit | 40.7M | 33.2M | 30.2M | 105.1M | 155.1M |
| Operating Expenses | |||||
| R&D Expense | 390.0K | 390.0K | 414.0K | 388.0K | 632.0K |
| SG&A Expense | 95.8M | 80.4M | 84.6M | 86.2M | 97.3M |
| General & Admin Expense | 43.3M | 60.2M | 62.9M | 64.3M | 91.7M |
| Selling & Marketing Expense | 52.5M | 20.3M | 21.7M | 21.9M | 5.6M |
| Other Expenses | (28.3M) | (54.4M) | 12.4M | 60.0M | 6.5M |
| Total Operating Expenses | 67.9M | 26.4M | 97.4M | 146.7M | 104.5M |
| Cost and Expenses | 297.4M | 263.5M | 306.1M | 397.1M | 338.1M |
| Operating Income (EBIT) | (27.2M) | 6.7M | (67.2M) | (41.6M) | 50.6M |
| Non-Operating | |||||
| Interest Income | — | 1.6M | 2.7M | 4.5M | 844.0K |
| Interest Expense | 18.1M | 19.7M | 20.6M | 24.2M | 14.7M |
| Net Interest Income | (18.1M) | (18.1M) | (17.9M) | (19.7M) | (13.8M) |
| Other Non-Op Income/Expense | (16.9M) | (50.8M) | (20.1M) | (19.7M) | (6.8M) |
| Non-Operating Income (excl Interest) | 40.0M | 31.2M | (530.0K) | (4.5M) | (7.9M) |
| EBT (Pre-Tax Income) | (44.1M) | (44.1M) | (87.3M) | (61.3M) | 43.8M |
| Income Tax Expense | (7.3M) | (7.3M) | (14.5M) | 2.2M | 93.0K |
| Bottom Line | |||||
| Net Income | (35.7M) | (35.7M) | (67.8M) | (62.0M) | 44.8M |
| Earnings from Cont. Ops | (36.8M) | (36.8M) | (72.8M) | (63.5M) | 43.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (35.7M) | (35.7M) | (67.8M) | (62.0M) | 44.8M |
| Per Share | |||||
| Basic EPS | ($3.55) | ($3.15) | ($7.10) | ($6.80) | $4.95 |
| Diluted EPS | ($3.55) | ($3.15) | ($7.10) | ($6.80) | $4.95 |
| Revenue Per Share | $26.65 | $23.79 | $25.00 | $39.02 | $42.85 |
| Shares | |||||
| Basic Shares Outstanding | 10.1M | 11.4M | 9.6M | 9.1M | 9.1M |
| Diluted Shares Outstanding | 10.1M | 11.4M | 9.6M | 9.1M | 9.1M |
| Profitability Metrics | |||||
| EBITDA | (55.3M) | (7.3M) | (51.3M) | (23.9M) | 70.2M |
| D&A | 11.9M | 17.1M | 15.4M | 13.2M | 11.7M |
| EBIT | (67.2M) | (24.4M) | (66.7M) | (37.1M) | 58.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025